NewEdge Advisors’s Verve Therapeutics VERV Stock Holding History

NewEdge Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-71	Closed	-$1.37K	–	4145
2022 Q4	$1.37K	Buy	+71	New	+$1.88K	﹤0.01%	2939

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NewEdge Advisors's VERV Position: Q1 2023 in Review

NewEdge Advisors sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 71 shares — an estimated $1.37K sold.

NewEdge Advisors first reported a position in VERV in Q4 2022 and held it in 1 quarter. The position peaked at $1.37K in Q4 2022. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

NewEdge Advisors reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 71 Verve Therapeutics shares in Q1 2023, an estimated $1.37K.
NewEdge Advisors first reported a position in Verve Therapeutics in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Verve Therapeutics position peaked at $1.37K in Q4 2022.
125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.